MedElevator Войти в исследования
← Поиск публикаций

DOI 10.4414/smw.2018.14588

Медицинская библиотека · Swiss medical weekly · 2018

Comparison of ESSDAI and ClinESSDAI in potential optimisation of trial outcomes in primary Sjögren's syndrome: examination of data from the UK Primary Sjögren's Syndrome Registry.

Dumusc Alexandre, Ng Wan-Fai, James Katherine, Griffiths Bridget, Price Elizabeth, Pease Colin, Emery Paul, Lanyon Peter, Jones Adrian, Bombardieri Michele, Sutcliffe Nurhan, Pitzalis Costantino, Gupta Monica, McLaren John, Cooper Annie, Giles Ian, Isenberg David, Saravanan Vadivelu, Coady David, Dasgupta Bhaskar, McHugh Neil, Young-Min Steven, Moots Robert, Gendi Nagui, Akil Mohammed, Barone Francesca, Fisher Benjamin, Rauz Saaeha, Richards Andrea, Bowman Simon

Сравнительное исследованиеСтатьяПеревод пока не подготовлен

Аннотация

OBJECTIVES

To assess the use of the Clinical EULAR Sjögren's Syndrome Disease Activity Index (ClinESSDAI), a version of the ESSDAI without the biological domain, for assessing potential eligibility and outcomes for clinical trials in patients with primary Sjögren's syndrome (pSS), according to the new ACR-EULAR classification criteria, from the UK Primary Sjögren's Syndrome Registry (UKPSSR).

METHODS

A total of 665 patients from the UKPSSR cohort were analysed at their time of inclusion in the registry. ESSDAI and ClinESSDAI were calculated for each patient.

RESULTS

For different disease activity index cut-off values, more potentially eligible participants were found when ClinESSDAI was used than with ESSDAI. The distribution of patients according to defined disease activity levels did not differ statistically (chi2 p = 0.57) between ESSDAI and ClinESSDAI for moderate disease activity (score ≥5 and <14; ESSDAI 36.4%; ClinESSDA 36.5%) or high disease activity (score ≥14; ESSDAI 5.4%; ClinESSDAI 6.8%). We did not find significant differences between the indexes in terms of activity levels for individual domains, with the exception of the articular domain. We found a good level of agreement between both indexes, and a positive correlation between lymphadenopathy and glandular domains with the use of either index and with different cut-off values. With the use of ClinESSDAI, the minimal clinically important improvement value was more often achievable with a one grade improvement of a single domain than with ESSDAI. We observed similar results when using the new ACR-EULAR classification criteria or the previously used American-European Consensus Group (AECG) classification criteria for pSS.

CONCLUSIONS

In the UKPSSR population, the use of ClinESSDAI instead of ESSDAI did not lead to significant changes in score distribution, potential eligibility or outcome measurement in trials, or in routine care when immunological tests are not available. These results need to be confirmed in other cohorts and with longitudinal data.

Для цитирования: Dumusc Alexandre, Ng Wan-Fai, James Katherine, Griffiths Bridget, Price Elizabeth, Pease Colin, Emery Paul, Lanyon Peter, Jones Adrian, Bombardieri Michele, Sutcliffe Nurhan, Pitzalis Costantino, Gupta Monica, McLaren John, Cooper Annie, Giles Ian, Isenberg David, Saravanan Vadivelu, Coady David, Dasgupta Bhaskar, McHugh Neil, Young-Min Steven, Moots Robert, Gendi Nagui, Akil Mohammed, Barone Francesca, Fisher Benjamin, Rauz Saaeha, Richards Andrea, Bowman Simon. Comparison of ESSDAI and ClinESSDAI in potential optimisation of trial outcomes in primary Sjögren's syndrome: examination of data from the UK Primary Sjögren's Syndrome Registry.. Swiss medical weekly. 2018. DOI: 10.4414/smw.2018.14588.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.